Syndrome News and Research

RSS
A Day in the Life of A Clinical Geneticist

A Day in the Life of A Clinical Geneticist

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Investigating SARS-CoV-2 genomics-informed outbreaks using new bioinformatics tools

Investigating SARS-CoV-2 genomics-informed outbreaks using new bioinformatics tools

Prediction of waning COVID-19 vaccine efficacy against Omicron variant

Prediction of waning COVID-19 vaccine efficacy against Omicron variant

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

Comparison of RBD/ACE2 receptor complex in wild type SARS-CoV-2 and Omicron variant

Comparison of RBD/ACE2 receptor complex in wild type SARS-CoV-2 and Omicron variant

Study provides a more effective treatment approach to preventing graft-versus-host-disease

Study provides a more effective treatment approach to preventing graft-versus-host-disease

Specific diets have less effect on IBS symptoms than expected

Specific diets have less effect on IBS symptoms than expected

New study demonstrates SARS-CoV-2 Omicron antibody escape

New study demonstrates SARS-CoV-2 Omicron antibody escape

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

Mutations in histone regulator protein linked to rare neurodevelopmental disorder, cancers

Mutations in histone regulator protein linked to rare neurodevelopmental disorder, cancers

Study suggests convalescent plasma appears safe but does not prevent SARS-CoV-2 infection

Study suggests convalescent plasma appears safe but does not prevent SARS-CoV-2 infection

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

T cell responses remain broadly robust against Omicron variant of SARS-CoV-2

T cell responses remain broadly robust against Omicron variant of SARS-CoV-2

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Vaccine effectiveness of mRNA-1273 during the emergence of the SARS-CoV-2 Delta variant

Vaccine effectiveness of mRNA-1273 during the emergence of the SARS-CoV-2 Delta variant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.